[CAS NO. 300657-03-8] BMS309403
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [300657-03-8]
Catalog
SLK-S6622
Brand
Selleck
CAS
300657-03-8
DESCRIPTION [300657-03-8]
Overview
| MDL | MFCD09991687 |
|---|---|
| Molecular Weight | 474.55 |
| Molecular Formula | C31H26N2O3 |
| SMILES | O=C(O)COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1073 mL | 10.5363 mL | 21.0726 mL |
| 5 mM | 0.4215 mL | 2.1073 mL | 4.2145 mL |
| 10 mM | 0.2107 mL | 1.0536 mL | 2.1073 mL |
| 50 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL |
Description
BMS309403 is a small-molecule inhibitor with nM affinity (Kd=4 nM for FABP4) and >100-fold selectivity against FABP5 as well as the heart isoform FABP3.
Targets
| FABP4 [1] (Cell-free assay) |
| 4 nM(Kd) |
In vitro
Treatment of BMS309403 (FABP4 inhibitor) comobined with SSO (CD36 inhibitor) significantly decreases the breast cancer cell viability, proliferative, migratory, and invasive abilities over 72 h. Inhibiting either at recommended concentrations does not significantly decrease the breast cancer cell viability over 72 h. Treatment with both SSO and BMS309403 results in clustering of cells and increased lipid content, indicating an inability to metabolise lipids resulting potentially in lipotoxicity-induced apoptosis.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.